Companies ADC Therapeutics SA
ADC Therapeutics (ADCT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me ADC Therapeutics SA’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers22nd pct.Of 20 peer CEOs
CEO pay, last three years
- $3,779,425FY2023
- $1,837,628FY2024
- $2,453,150FY2025
CEO total pay was $2,453,150 in fiscal 2025, up from $1,837,628 in fiscal 2024.
FY2025: salary $776,084 · bonus $0 · stock awards $1,046,500 · option awards $0
Executives and directors
Ameet Mallik · CEOJose Carmona · CFOMohamed Zaki · Chief Medical OfficerJean-Pierre Bizzari · Independent DirectorPeter Hug · Lead Independent DirectorRobert Azelby · Independent DirectorRon Squarer · Chair of the BoardThomas Pfisterer · Independent DirectorTimothy Coughlin · Independent DirectorTyrell J. Rivers · Independent DirectorVictor Sandor · Independent DirectorViviane Monges · Independent Director
Frequently asked questions
Who was the highest-paid executive at ADC Therapeutics SA in fiscal 2025?
As disclosed, Ameet Mallik (Chief Executive Officer) was the highest-paid executive at ADC Therapeutics SA in fiscal 2025, with total compensation of $2,453,150.
How does ADC Therapeutics SA's chief executive pay compare to its disclosed peer group?
As disclosed, Ameet Mallik's total compensation ranked at the 22nd percentile of ADC Therapeutics SA's disclosed peer group.
How much does ADC Therapeutics SA spend in total on board compensation for fiscal 2025?
As disclosed, ADC Therapeutics SA reported total board compensation of $1,611,009 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ameet Mallik | $776,084 | $0 | $1,046,500 | $0 | $582,063 | $0 | $48,503 | $2,453,150 |
| Chief Executive Officer | ||||||||
| Mohamed Zaki | 690,121 | 0 | 370,300 | 0 | 431,325 | 0 | 23,820 | 1,515,566 |
| Chief Medical Officer | ||||||||
| Jose Carmona | 525,208 | 0 | 386,400 | 0 | 328,255 | 0 | 7,140 | 1,247,003 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Ameet Mallik | $2,453,150 | $1,837,628 | $3,779,425 | ↑ +615,522 |
| Mohamed Zaki | 1,515,566 | 1,009,513 | 4,403,851 | ↑ +506,053 |
| Jose Carmona | 1,247,003 | 933,585 | 1,259,357 | ↑ +313,418 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation philosophy is designed to reward financial and operational performance, support our business strategies and offer competitive compensation arrangements to both attract and retain key individuals.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jose Carmona | RSU | 2025-02-13 | — | — | 240,000 | — | $386,400 |
| Ameet Mallik | RSU | 2025-02-13 | — | — | 650,000 | — | 1,046,500 |
| Mohamed Zaki | RSU | 2025-02-13 | — | — | 230,000 | — | 370,300 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jose Carmona | $386,400 | $0 | $0 | 0.0% |
| Ameet Mallik | 1,046,500 | 0 | 0 | 0.0% |
| Mohamed Zaki | 370,300 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mohamed Zaki | Option | 19,444 | 3.59 | — |
| Ameet Mallik | Option | 111,246 | 10.95 | — |
| Jose Carmona | Option | 115,000 | 3.04 | — |
| Ameet Mallik | Option | 195,312 | 1.99 | — |
| Mohamed Zaki | RSU | 230,000 | — | 811,900 |
| Jose Carmona | RSU | 240,000 | — | 847,200 |
| Ameet Mallik | RSU | 650,000 | — | 2,294,500 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Timothy CoughlinIndependent · Audit (Chair) | $55,529 | $143,600 | $232,000 | — | $0 | $431,129 |
| Peter HugIndependent · Lead Independent Director · Compensation (Chair) · Nominating and Corporate Governance | 90,000 | 143,600 | 0 | — | 17,368 | 250,968 |
| Ron SquarerNot independent · Board Chair | 85,000 | 143,600 | 0 | — | 20,597 | 249,197 |
| Viviane MongesIndependent · Audit · Nominating and Corporate Governance | 71,346 | 143,600 | 0 | — | 31,468 | 246,414 |
| Victor SandorIndependent · Compensation · Science and Technology (Chair) | 67,500 | 143,600 | 0 | — | 0 | 211,100 |
| Robert AzelbyIndependent · Audit · Compensation | 67,500 | 143,600 | 0 | — | 0 | 211,100 |
| Jean-Pierre BizzariIndependent · Nominating and Corporate Governance (Chair) · Science and Technology | 62,500 | 143,600 | 0 | — | 0 | 206,100 |
| Thomas PfistererIndependent | 22,500 | 0 | 0 | — | 14,501 | 37,001 |
| Tyrell J. RiversIndependent · Science and Technology | 0 | 0 | 0 | — | 0 | 0 |
| Ameet MallikEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $143,600 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $521,875 |
| Equity awards (grant-date value) | $1,005,200 |
| All other compensation | $83,934 |
| Total cost of the board | $1,611,009 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names ADC Therapeutics as a peer
Companies that benchmark against ADCT
No companies currently name ADCT as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
FATE Fate Therapeutics, Inc.QURE uniQure N.V.URGN Urogen Pharma Ltd.AKBA Akebia Therapeutics, Inc.AQST Aquestive Therapeutics, Inc. Jose Pepe CarmonaMRSN Mersana Therapeutics, Inc.ESPR Esperion Therapeutics, Inc.ALLO Allogene Therapeutics, Inc.NKTR Nektar TherapeuticsXFOR X4 PharmaceuticalsIMNM Immunome, Inc.ZYME Zymeworks Inc.PBYI Puma Biotechnology, Inc.PYXS Pyxis Oncology, Inc.RIGL Rigel PharmaceuticalsMGNX MacroGenicsYMAB Y-mAbs TherapeuticsHRTX Heron TherapeuticsKPTI KaryoPharm Therapeutics Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunome, Inc. | 2025 | Clay Siegall | $735,000 | $0 | $6,272,810 | $661,500 | $7,682,601 |
| 2 | Zymeworks Inc. | 2025 | Kenneth Galbraith | 656,763 | 2,538,240 | 2,366,565 | 340,990 | 6,613,180 |
| 3 | Nektar Therapeutics | 2025 | Howard Robin | 1,106,282 | 942,081 | 2,986,535 | 1,106,282 | 6,256,954 |
| 4 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 5 | Akebia Therapeutics, Inc. | 2025 | John Butler | 864,010 | 2,164,338 | 2,024,798 | 580,973 | 5,652,339 |
| 6 | Rigel Pharmaceuticals | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 7 | Y-mAbs Therapeutics | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 8 | Urogen Pharma Ltd. | 2025 | Elizabeth Barrett | 855,590 | 2,122,211 | 0 | 516,263 | 4,310,624 |
| 9 | Esperion Therapeutics, Inc. | 2025 | Sheldon Koenig | 770,833 | 1,260,000 | 847,929 | 639,375 | 3,535,512 |
| 10 | Heron Therapeutics | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 11 | Aquestive Therapeutics, Inc. | 2025 | Daniel Barber | 659,885 | 1,547,342 | 877,200 | 409,132 | 3,493,559 |
| 12 | uniQure NV | 2025 | Matthew Kapusta | 676,170 | 1,079,100 | 1,155,960 | 345,117 | 3,287,434 |
| 13 | Puma Biotechnology, Inc. | 2025 | Alan Auerbach | 931,333 | 551,549 | 535,513 | 1,027,307 | 3,062,337 |
| 14 | X4 Pharmaceuticals | 2025 | Paula Ragan | 420,170 | 1,081,575 | 0 | 0 | 2,640,569 |
| 15 | ADC Therapeutics SA | 2025 | Ameet Mallik | 776,084 | 1,046,500 | 0 | 582,063 | 2,453,150 |
| 16 | KaryoPharm Therapeutics Inc. | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 17 | Fate Therapeutics, Inc. | 2025 | Bahram Valamehr | 600,000 | 0 | 1,283,868 | 360,000 | 2,248,568 |
| 18 | MacroGenics | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 19 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| — | Pyxis Oncology, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| ADC Therapeutics SA | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Akebia Therapeutics, Inc. | 90% | Options 50 · RSU 25 · MSU 25 | No | Pearl Meyer |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Aquestive Therapeutics, Inc. | not disclosed | Options 42 · PSU 30 · RSU 28 | No | Aon |
| Esperion Therapeutics, Inc. | 110% | not disclosed | not disclosed | not disclosed |
| Fate Therapeutics, Inc. | 100% | Options 100 | No | Aon's Human Capital Solutions practice (Radford) |
| Heron Therapeutics | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| Immunome, Inc. | 150% | Options 100 | not disclosed | Aon |
| KaryoPharm Therapeutics Inc. | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| MacroGenics | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Mersana Therapeutics, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Nektar Therapeutics | 100% | not disclosed | No | Aon |
| Puma Biotechnology, Inc. | 169.7% | Options 50 · RSU 50 | not disclosed | Compensia |
| Pyxis Oncology, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Rigel Pharmaceuticals | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| uniQure NV | not disclosed | Options 50 · RSU 50 | No | WTW (Willis Towers Watson) |
| Urogen Pharma Ltd. | 80% | RSU 50 · PSU 50 | No | Compensia, Inc. |
| X4 Pharmaceuticals | not disclosed | not disclosed | not disclosed | not disclosed |
| Y-mAbs Therapeutics | 85.6% | not disclosed | No | Aon |
| Zymeworks Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Aon plc (Talent Solutions practice) |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-01 | 64,172,306 | 1,271,205 | 3,903,859 | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-01 | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (40 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Ameet Mallik. DEF 14A, filed 2026-04-20. Section “Executive Compensation” · page 27. As printed: 2,453,150. View filing ↗
- Section 01, Mohamed Zaki. DEF 14A, filed 2026-04-20. Section “Executive Compensation”. As printed: 1,515,566. View filing ↗
- Section 01, Jose Carmona. DEF 14A, filed 2026-04-20. Section “Executive Compensation”. As printed: 1,247,003. View filing ↗
- Section 03, Jose Carmona RSU. DEF 14A, filed 2026-04-20. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ameet Mallik RSU. DEF 14A, filed 2026-04-20. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mohamed Zaki RSU. DEF 14A, filed 2026-04-20. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-10. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Timothy Coughlin. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 431,129. View filing ↗
- Section 08, Peter Hug. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 250,968. View filing ↗
- Section 08, Ron Squarer. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 249,197. View filing ↗
- Section 08, Viviane Monges. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 246,414. View filing ↗
- Section 08, Victor Sandor. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 211,100. View filing ↗
- Section 08, Robert Azelby. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 211,100. View filing ↗
- Section 08, Jean-Pierre Bizzari. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 206,100. View filing ↗
- Section 08, Thomas Pfisterer. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 37,001. View filing ↗
- Section 08, Tyrell J. Rivers. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Ameet Mallik. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-04-20. Item 5.07 · say-on-pay result. As reported: — (votes for as printed: 64,172,306). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 521,875 + equity 1,005,200 + all other 83,934 = 1,611,009, summed across the director compensation table rows.
- Immunome, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Immunome, Inc.'s own proxy. As printed: 7,682,601. View filing ↗
- Zymeworks Inc., Section 10b CEO total. DEF 14A, filed 2026-10-26. CEO total compensation as printed in Zymeworks Inc.'s own proxy. As printed: 6,613,180. View filing ↗
- Nektar Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Nektar Therapeutics's own proxy. As printed: 6,256,954. View filing ↗
- Allogene Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. View filing ↗
- Akebia Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Akebia Therapeutics, Inc.'s own proxy. As printed: 5,652,339. View filing ↗
- Rigel Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals's own proxy. As printed: 4,658,805. View filing ↗
- Y-mAbs Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-05-30. CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. View filing ↗
- Urogen Pharma Ltd., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Urogen Pharma Ltd.'s own proxy. As printed: 4,310,624. View filing ↗
- Esperion Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. View filing ↗
- Heron Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics's own proxy. As printed: 3,516,291. View filing ↗
- Aquestive Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Aquestive Therapeutics, Inc.'s own proxy. As printed: 3,493,559. View filing ↗
- uniQure NV, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in uniQure NV's own proxy. As printed: 3,287,434. View filing ↗
- Puma Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Puma Biotechnology, Inc.'s own proxy. As printed: 3,062,337. View filing ↗
- X4 Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in X4 Pharmaceuticals's own proxy. As printed: 2,640,569. View filing ↗
- ADC Therapeutics SA (subject), Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ADC Therapeutics SA's own proxy. As printed: 2,453,150. View filing ↗
- KaryoPharm Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in KaryoPharm Therapeutics Inc.'s own proxy. As printed: 2,320,902. View filing ↗
- Fate Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Fate Therapeutics, Inc.'s own proxy. As printed: 2,248,568. View filing ↗
- MacroGenics, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics's own proxy. As printed: 2,078,854. View filing ↗
- Mersana Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. View filing ↗